mlsanityData to 7 Oct 2026

Auxiliary Discrminator Sequence Generative Adversarial Networks (ADSeqGAN) for Few Sample Molecule Generation

arXiv 2502.16446 ↗First posted 23 Feb 2025cs.LG cs.AI q-bio.BMcited by 0

Not on the map. Why?

Abstract (arXiv)

In this work, we introduce Auxiliary Discriminator Sequence Generative Adversarial Networks (ADSeqGAN), a novel approach for molecular generation in small-sample datasets. Traditional generative models often struggle with limited training data, particularly in drug discovery, where molecular datasets for specific therapeutic targets, such as nucleic acids binders and central nervous system (CNS) drugs, are scarce. ADSeqGAN addresses this challenge by integrating an auxiliary random forest classifier as an additional discriminator into the GAN framework, significantly improves molecular generation quality and class specificity. Our method incorporates pretrained generator and Wasserstein distance to enhance training stability and diversity. We evaluate ADSeqGAN across three representative cases. First, on nucleic acid- and protein-targeting molecules, ADSeqGAN shows superior capability in generating nucleic acid binders compared to baseline models. Second, through oversampling, it markedly improves CNS drug generation, achieving higher yields than traditional de novo models. Third, in cannabinoid receptor type 1 (CB1) ligand design, ADSeqGAN generates novel druglike molecules, with 32.8% predicted actives surpassing hit rates of CB1-focused and general-purpose libraries when assessed by a target-specific LRIP-SF scoring function. Overall, ADSeqGAN offers a versatile framework for molecular design in data-scarce scenarios, with demonstrated applications in nucleic acid binders, CNS drugs, and CB1 ligands.

Key facts. No citing papers in the map yet (data through 7 Oct 2026). Builds on 25 of its 92 references that are in the map. First posted on arXiv 23 Feb 2025.

Builds on

25 of 92 references.

References · 25

  1. 2018The Unreasonable Effectiveness of Deep Features as a Perceptual Metriccited by 11,029
  2. 2018A Style-Based Generator Architecture for Generative Adversarial Networkscited by 5,986
  3. 2022Generative Adversarial Networkscited by 5,603
  4. 2017Progressive Growing of GANs for Improved Quality, Stability, and Variationcited by 2,967
  5. 2017Improved Training of Wasserstein GANscited by 2,223
  6. 2013Rich feature hierarchies for accurate object detection and semantic segmentationcited by 2,160
  7. 2015Unsupervised Representation Learning with Deep Convolutional Generative Adversarial Networkscited by 2,048
  8. 2021Alias-Free Generative Adversarial Networkscited by 1,181
  9. 2014Convolutional Neural Networks for Sentence Classificationcited by 1,124
  10. 2017Deep Reinforcement Learning that Matterscited by 727
  11. 2019A Closer Look at Few-shot Classificationcited by 679
  12. 2017Wasserstein GANcited by 635
13 more
  1. 2016Conditional Image Synthesis With Auxiliary Classifier GANscited by 562
  2. 2018MolGAN: An implicit generative model for small molecular graphscited by 392
  3. 2016SeqGAN: Sequence Generative Adversarial Nets with Policy Gradientcited by 375
  4. 2017Are GANs Created Equal? A Large-Scale Studycited by 267
  5. 2018Fr'echet ChemNet Distance: A metric for generative models for molecules in drug discoverycited by 191
  6. 2017Objective-Reinforced Generative Adversarial Networks (ORGAN) for Sequence Generation Modelscited by 116
  7. 2017Reproducibility of Benchmarked Deep Reinforcement Learning Tasks for Continuous Controlcited by 92
  8. 2021Ensembling Off-the-shelf Models for GAN Trainingcited by 84
  9. 2016Generative Multi-Adversarial Networkscited by 60
  10. 2025The GAN is dead; long live the GAN! A Modern GAN Baselinecited by 57
  11. 2019Multi-objective training of Generative Adversarial Networks with multiple discriminatorscited by 24
  12. 2023Domain-Agnostic Molecular Generation with Chemical Feedbackcited by 21
  13. 2023ChatGPT in Drug Discovery: A Case Study on Anti-Cocaine Addiction Drug Development with Chatbotscited by 4

Built on by

Not cited yet.